查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1373202

活生物治療產品和微生物 CDMO 市場 - 2018-2028 年全球產業規模、佔有率、趨勢、競爭、機會和預測，按應用、按產品、按製劑類型、按營運規模、按地區和競爭細分

Live Biotherapeutics Products & Microbe CDMO Market - Global Industry Size, Share, Trends, Competition, Opportunity, & Forecast, 2018-2028 Segmented By Application, By Product, By Type of Formulation, By Scale of Operation, By Region & Competition
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球活體生物治療產品 (LBP) 市場在 2024-2028 年預測期內將以高年複合成長率成長。心血管疾病、糖尿病、慢性呼吸道疾病、癌症和慢性腎臟病等某些慢性疾病在各國的盛行率不斷上升，預計將在預測期內為全球活體生物治療產品和微生物CDMO 市場帶來利潤豐厚的成長。此外，世界各地的人們對身心健康個人化藥物的日益偏好預計將在未來幾年推動活體生物療法產品和微生物 CDMO 市場的成長。

市場區隔

全球活生物治療產品和微生物 CDMO 市場根據應用、產品、製劑類型、營運規模、公司和地區進行細分。從應用來看，活體生物治療產品和微生物CDMO市場分為艱難梭菌、克隆氏症、IBS、糖尿病等。根據產品，全球活體生物治療產品和微生物 CDMO 市場分為 API 和 FDF。依製劑類型，市場分為固體製劑、口服液、注射劑等。根據營運規模，全球活體生物治療產品和微生物 CDMO 市場分為臨床前規模營運、臨床規模營運和商業規模營運。

市場參與者

Arranta Bio Holdings LLC.、4D Pharma plc.、Cerbios-Pharma SA、Biose Industrie、Assembly Biosciences, Inc.、Wacker Chemie AG、Quay Pharmaceuticals Ltd.、Bacthera AG、LONZA 和Inpac Probiotics 是全球活性生物治療藥物的主要參與者產品和微生物 CDMO 市場。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球活體生物療法產品和微生物 CDMO 市場還分為以下幾類。

活體生物治療產品與微生物 CDMO 市場（按應用）：

  • 艱難梭菌
  • 克隆氏症
  • 腸躁症
  • 糖尿病
  • 其他

活體生物治療產品和微生物 CDMO 市場（副產品）：

  • 蜜蜂
  • FDF

活生物治療產品和微生物 CDMO 市場（按配方類型）：

  • 固體製劑
  • 口服液
  • 注射劑
  • 其他

活生物治療產品和微生物 CDMO 市場，依營運規模分類：

  • 臨床前規模營運
  • 臨床規模營運
  • 商業規模營運

活生物治療產品和微生物 CDMO 市場，按地區：

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 亞太
  • 中國
  • 印度
  • 韓國
  • 澳洲
  • 日本
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 南美洲
  • 巴西
  • 阿根廷
  • 哥倫比亞
  • 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

競爭格局

  • 公司概況：全球活體生物治療產品和微生物 CDMO 市場主要公司的詳細分析

可用的客製化：

  • 根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球活體生物治療產品與微生物 CDMO 市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按應用（艱難梭菌、克隆氏症、IBS、糖尿病、其他）
    • 按產品（API、FDF）
    • 依製劑類型（固體製劑、口服液、注射劑、其他）
    • 依營運規模分類（臨床前規模營運、臨床規模營運、商業規模營運）
    • 按地區
    • 按公司分類 (2022)
  • 產品市場地圖

第 6 章：北美活體生物治療產品與微生物 CDMO 市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按應用
    • 按產品分類
    • 依配方類型
    • 按經營規模
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲活體生物治療產品與微生物 CDMO 市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按應用
    • 按產品分類
    • 依配方類型
    • 按經營規模
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區活體生物治療產品與微生物 CDMO 市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按應用
    • 按產品分類
    • 依配方類型
    • 按經營規模
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲活體生物治療產品與微生物 CDMO 市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按應用
    • 按產品分類
    • 依配方類型
    • 按經營規模
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲活體生物治療產品和微生物 CDMO 市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市佔率及預測
    • 按應用
    • 按產品分類
    • 依配方類型
    • 按經營規模
    • 按國家/地區
  • MEA：國家分析
    • 南非活體生物治療產品與微生物 CDMO
    • 沙烏地阿拉伯活體生物治療產品和微生物 CDMO
    • 阿拉伯聯合大公國活體生物治療產品與微生物 CDMO

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Arranta Bio Holdings LLC.
    • 4D Pharma plc.
    • Cerbios-Pharma SA
    • Biose Industrie
    • Assembly Biosciences, Inc.
    • Wacker Chemie AG
    • Quay Pharmaceuticals Ltd.
    • Bacthera AG
    • LONZA
    • Inpac Probiotics

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 15742

Global Live Biotherapeutics Products (LBPs) Market is anticipated to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of certain chronic diseases such as cardiovascular diseases, diabetes, chronic respiratory diseases, cancer, and chronic kidney disease across various countries are expected to register a lucrative growth to global live biotherapeutics products and microbe CDMO market in the forecast period. Moreover, growing preference of people around the world towards personalized medicines for physical and mental health are expected to propel the growth of live biotherapeutics products and microbe CDMO market in upcoming years.

Live Biotherapeutics Products (LBPs) are a type of therapeutic product that utilize living microbes to treat various medical conditions. Some of the commonly available live biotherapeutics products available in the market includes Lactobacillus acidophilus, Bifidobacterium lactis, Streptococcus thermophilus, Saccharomyces boulardii, and Escherichia coli Nissle. These microbes, such as bacteria or yeast, are typically found in the gut microbiome and play a critical role in maintaining human health. LBPs work by introducing these microbes into the body in a controlled manner to restore or enhance their function.

A Microbial Contract Development and Manufacturing Organization (CDMO) is a company that specializes in the development and manufacturing of microbial-based products, including live biotherapeutics product. Microbe CDMOs can provide a range of services, including strain development, fermentation optimization, downstream processing, and quality control. CDMO activities can be broadly categorized into three categories such as product development, manufacture of active pharmaceutical ingredients (API), and manufacture of finished dosage forms (FDF). There are around 500 Contract Development and Manufacturing Organization established in the world. Among them, Switzerland-based Lonza is the leading CDMO industry functioning across the world.

Increasing Prevalence of Chronic Diseases

Chronic diseases are defined broadly as conditions that progress slowly and persist over an extended period. Some of the major risk factors which lead to the development of chronic illness inside human body include intake of unbalanced diet, consumption of alcohol, smoking cigarettes, physical inactivity, and others. Cardiovascular diseases, Cancer, and diabetes are three most prevailing chronic diseases in the world which are thereby increasing the mortality of every country in the forecast period. According to the report published by Pan American Health Organization (PAHO) in 2019, Ischemic heart disease accounted for 73.6 deaths per 100,000 population in the world, followed by stroke with 32.3 deaths, other circulatory diseases with 14.8 deaths, hypersensitive heart disease with 10.6 deaths, cardiomyopathy, myocarditis, and endocarditis with 5.1 deaths and rheumatic heart disease with 0.7 deaths of total population across the world. After cardiovascular diseases, cancer has been reported as second major reason behind the growing mortality rate of various developing countries across the world. As per the report published by World Health Organization (WHO) in 2022, it has been observed that lung cancer has been the most prominent type of cancer prevailing across the world accounting for 1.80 million deaths, followed by 9,16,000 deaths caused by colon and rectum cancer, 8,30,000 deaths due to liver cancer, 7,69,000 deaths by stomach cancer and 6,85,000 deaths caused by breast cancer. Live biotherapeutic products are designed to modulate the gut microbiome which plays a major role in maintaining a healthy immune system and preventing chronic diseases. Moreover, microbe CDMOs provide customized solutions for the development, manufacturing, and scale-up of microbial products for clinical trials and commercial use. Other health problems which can affect the human body along with prevalence of chronic diseases are expected to propel the growth of global biotherapeutics products and microbe CDMO market in the forecast period.

Rise in Demand for Personalized Medicines

The growing demand for personalized medicines is indeed a significant driver of the global biotherapeutics products and microbe CDMO (Contract Development and Manufacturing Organization) market. Biotherapeutics products, including personalized medicines, are a major growth area of pharmaceutical industry. These products are derived from biological sources, such as living cells, and can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Moreover, microbe CDMOs are specialized in the development and manufacturing of biotherapeutics products, including personalized medicines, using microbial systems such as bacteria, yeast, and fungi. These CDMOs offer a range of services, including cell line development, process development, analytical development, and manufacturing. The growing demand for personalized medicines has led to an increase in the demand for these services which are further projected to register an impressive growth to Global Biotherapeutics Products and Microbe CDMO market in upcoming years.

Market Segmentation

Global live biotherapeutics products and microbe CDMO market is segmented based on application, product, type of formulation, scale of operation, company, and region. In terms of application, the live biotherapeutics products and microbe CDMO market is categorized into C.difficle, Crohns disease, IBS, diabetes, and others. Based on product, the global live biotherapeutics products and microbe CDMO market is fragmented into APIs and FDFs. Based on type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on scale of operation, the global live biotherapeutics products and microbe CDMO market is fragmented into preclinical scale operations, clinical scale operations, and commercial scale operations.

Market Players

Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, and Inpac Probiotics are the major players of global live biotherapeutics products and microbe CDMO market.

Report Scope:

In this report, Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into following categories, in addition to the industry trends which have also been detailed below.

Live Biotherapeutics Products and Microbe CDMO Market, By Application:

  • C.difficle
  • Crohns disease
  • IBS
  • Diabetes
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Product:

  • APIs
  • FDFs

Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation:

  • Solid Formulations
  • Oral Liquids
  • Injectables
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation:

  • Preclinical Scale Operations
  • Clinical Scale Operations
  • Commercial Scale Operations

Live Biotherapeutics Products and Microbe CDMO Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Live Biotherapeutics Products and Microbe CDMO Market

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)
    • 5.2.2. By Product (APIs, FDFs)
    • 5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)
    • 5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Product Market Map

6. North America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Product
    • 6.2.3. By Type of Formulation
    • 6.2.4. By Scale of Operation
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value & Volume
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Type of Formulation
        • 6.3.1.2.4. By Scale of operation
    • 6.3.2. Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value & Volume
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Type of Formulation
        • 6.3.2.2.4. By Scale of Operation
    • 6.3.3. Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value & Volume
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Type of Formulation
        • 6.3.3.2.4. By Scale of Operation

7. Europe Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Product
    • 7.2.3. By Type of Formulation
    • 7.2.4. By Scale of Operation
  • 7.3 Europe: Country Analysis
    • 7.3.1. France Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value & Volume
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Type of Formulation
        • 7.3.1.2.4. By Scale of Operation
    • 7.3.2. Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value & Volume
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Type of Formulation
        • 7.3.2.2.4. By Scale of Operation
    • 7.3.3. United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value & Volume
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Type of Formulation
        • 7.3.3.2.4. By Scale of Operation
    • 7.3.4. Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value & Volume
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Type of Formulation
        • 7.3.4.2.4. By Scale of Operation
    • 7.3.5. Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value & Volume
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Type of Formulation
        • 7.3.5.2.4. By Scale of Operation

8. Asia-Pacific Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Product
    • 8.2.3. By Type of Formulation
    • 8.2.4. By Scale of Operation
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value & Volume
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Type of Formulation
        • 8.3.1.2.4. By Scale of Operation
    • 8.3.2. India Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value & Volume
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Type of Formulation
        • 8.3.2.2.4. By Scale of Operation
    • 8.3.3. South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value & Volume
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Type of Formulation
        • 8.3.3.2.4. By Scale of Operation
    • 8.3.4. Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value & Volume
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Type of Formulation
        • 8.3.4.2.4. By Scale of Operation
    • 8.3.5. Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value & Volume
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Type of Formulation
        • 8.3.5.2.4. By Scale of Operation

9. South America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Product
    • 9.2.3. By Type of Formulation
    • 9.2.4. By Scale of Operation
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value & Volume
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Type of Formulation
        • 9.3.1.2.4. BY Scale of Operation
    • 9.3.2. Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value & Volume
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Type of Formulation
        • 9.3.2.2.4. By Scale of Operation
    • 9.3.3. Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value & Volume
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Type of Formulation
        • 9.3.3.2.4. By Scale of Operation

10. Middle East and Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Product
    • 10.2.3. By Type of Formulation
    • 10.2.4. By Scale of Operation
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value & Volume
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Type of Formulation
        • 10.3.1.2.4. By Scale of Operation
    • 10.3.2. Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value & Volume
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Type of Formulation
        • 10.3.2.2.4. By Scale of Operation
    • 10.3.3. UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value & Volume
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Type of Formulation
        • 10.3.3.2.4. By Scale of Operation

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Arranta Bio Holdings LLC.
    • 15.6.2. 4D Pharma plc.
    • 15.6.3. Cerbios-Pharma S.A.
    • 15.6.4. Biose Industrie
    • 15.6.5. Assembly Biosciences, Inc.
    • 15.6.6. Wacker Chemie AG
    • 15.6.7. Quay Pharmaceuticals Ltd.
    • 15.6.8. Bacthera AG
    • 15.6.9. LONZA
    • 15.6.10. Inpac Probiotics

16. Strategic Recommendations

17. About Us & Disclaimer